Other and unspecified disorders of prostate (N42)
Browse all the diagnosis codes used for other and unspecified disorders of prostate (N42). For easy navigation, the diagnosis codes are sorted in alphabetical order and grouped by sections. Each section is clearly marked with its description, and the corresponding three-digit code range. This format makes it simple to browse diagnosis codes in this chapter or section and find what you're looking for. We've also added green checkmark icons to label billable codes, and red warning icons for non-billable ones. This makes it easy to identify which codes can be billed.
Diseases of the genitourinary system (N00–N99)
Diseases of male genital organs (N40-N53)
N42 Other and unspecified disorders of prostate
- N42.0 Calculus of prostate
- N42.1 Congestion and hemorrhage of prostate
N42.3 Dysplasia of prostate
- N42.30 Unspecified dysplasia of prostate
- N42.31 Prostatic intraepithelial neoplasia
- N42.32 Atypical small acinar proliferation of prostate
- N42.39 Other dysplasia of prostate
N42.8 Other specified disorders of prostate
- N42.81 Prostatodynia syndrome
- N42.82 Prostatosis syndrome
- N42.83 Cyst of prostate
- N42.89 Other specified disorders of prostate
- N42.9 Disorder of prostate, unspecified
Other and unspecified disorders of prostate (N42)
Clinical Terms
The following clinical terms provide additional context, helping users better understand the clinical background and common associations for each diagnosis listed in this section. Including related terms alongside ICD-10-CM codes supports coders, billers, and healthcare professionals in improving accuracy, enhancing documentation, and facilitating research or patient education.
Prostatic Intraepithelial Neoplasia
A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer.
